Instrumento Inactivo

Otros idiomas Propanc Biopharma Inc Other OTC

Acciones

US74346N1072

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Propanc Biopharma Receives Certificate of Grant for Proenzymes Composition Patent from Japanese Patent Office	26/06
Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	25/06
Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding	20/06
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	17/06
Propanc Biopharma, Inc. Enters into and Closed a Loan Agreement with an Investor	13/06
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	31/05
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05
Propanc Biopharma : Material Agreement - Form 8-K	22/04
Propanc Biopharma Receives Certificate of Grant for Composition of Proenzymes for Cancer Treatment Patent from European Patent Office	17/04
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	16/04
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	16/04
Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment, an inside Look at Drug Development and Strategic Financing	09/04
Propanc Biopharma : Material Agreement - Form 8-K	11/03
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	01/03
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study	23/02
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	20/02
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	16/01
Propanc Biopharma's Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP	14/12
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	11/12
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	04/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Propanc Biopharma Inc Other OTC

Acciones

US74346N1072

Otros idiomas

Filtros